

## A War on Two Fronts: Cancer Care in the Time of COVID-19

Alexander Kutikov, MD; David S. Weinberg, MD, MSc; Martin J. Edelman, MD; Eric M. Horwitz, MD; Robert G. Uzzo, MD, MBA; and Richard I. Fisher, MD

The rapidly expanding coronavirus disease 2019 (COVID-19) (SARS-CoV-2) acute respiratory pandemic has assaulted all aspects of daily life (1, 2). As of 25 March 2020, there were more than 450 000 cases worldwide. In the absence of a vaccine or a therapeutic agent, a “social distancing” strategy is the primary intervention to hamper the spread of infection (1). A major fear of most governments and individuals is the heavy impact on the health care delivery system. Cumbersome diagnostic testing, inadequate protective supplies for frontline providers and first responders, and limited hospital capacity—including intensive care—have all conspired to create an environment compared to warfare (3).

During this extraordinary time, the oncology community faces unprecedented challenges. According to the American Cancer Society, this year nearly 5000 new cases of cancer will be diagnosed per day in the United States. Initial reports suggest that COVID-19 can be particularly lethal in patients with cancer (2). As such, oncology specialists as well as other providers regularly involved in the diagnosis, active treatment, and longitudinal follow-up of patients with cancer must consider how to 1) balance a delay in cancer diagnosis or treatment against the risk for a potential COVID-19 exposure, 2) mitigate the risks for significant care disruptions associated with social distancing behaviors, and 3) manage the appropriate allocation of limited health care resources in this unprecedented time of health care crisis.

### RISK FROM DELAY OF TREATMENT VERSUS HARM OF COVID-19 EXPOSURE

It is known that COVID-19 disproportionately harms elderly persons and those with comorbid conditions (4). A current or past cancer diagnosis appears to place infected patients at substantially increased risk. In early reports from China, patients with cancer who acquired COVID-19 had a higher risk for significant morbidity, including requirements for ventilatory support or death (hazard ratio, 3.56 [95% CI, 1.65 to 7.69]) (2). Thus, in patients with cancer, the utility of intervention must be weighed against the risk for inadvertent COVID-19 exposure in the health care system, especially during the initial weeks of the pandemic, when the risk for viral dissemination cannot be quantified and remains largely unknown.

Furthermore, the potential for increased vulnerability to adverse outcomes from COVID-19 after oncologic treatments, such as surgery, systemic chemotherapy, or radiation therapy, must be considered. The **Figure** provides guidance for nonspecialists in oncology about the effects of delayed diagnosis or treatment in com-

mon cancer scenarios. Many solid tumors (such as lung or pancreatic cancer) and some hematologic cancers (such as acute leukemia) require immediate diagnosis and treatment. However, other common early-stage cancers (breast, prostate, cervical, nonmelanoma skin) may not. The quality of evidence in some cases is inadequate to support “one size fits all” statements applicable to every patient. However, experienced oncology providers should feel confident exercising judgment regarding which patients need to initiate or continue treatment owing to their tumor’s more aggressive biology versus those who can tolerate a delay. Decision making may change as efforts by the health care system to mitigate risks for exposure to COVID-19 improve (5). Indeed, consensus recommendations swiftly began to appear to help providers make appropriate triage decisions (6). For persons with advanced oncologic disease, futility of treatment in the context of COVID-19 must be frankly considered and discussed.

### SOCIAL DISTANCING AND ITS COMPROMISE DURING CARE DELIVERY


Restrictive social distancing has been promoted as effective to stem pandemics in the past and appears to be the most promising strategy during this early stage of the COVID-19 crisis (1, 7). This strategy emphasizes the concept of “mitigation,” where the number of severe cases in the health system at a given time is minimized to reduce preventable deaths from resource overload (1).

Every patient who engages with the traditional oncology care delivery system significantly disrupts this social distancing tactic, resulting in innumerable ripple effects. Clinic visits, surgical stays, infusion sessions, radiation planning and treatment appointments, hospital admissions, phlebotomy visits for laboratory tests, and radiographic imaging studies—all often attended with family members in tow—result in a massive number of personal contact points and many potential opportunities for viral transmission.

Another consideration are clinical trials, which are a unique part of medical oncology and cancer care in general. Entry into a research study is considered standard of care for many patients with locally advanced or advanced cancer. Most trials require additional appointments and tests, further increasing the potential for infection. Furthermore, the supply of novel drugs, both in terms of manufacture and distribution, may be compromised. The National Cancer Institute and the U.S. Food and Drug Administration have issued preliminary guidance regarding these issues (8), but there is an urgent need for clear instruction and methods to

Figure. Guidance on decisions about immediate cancer treatment during the COVID-19 crisis.

Decision Regarding Immediate Cancer Treatment During COVID-19 Crisis		Risk for Significant Morbidity From COVID-19 (comorbidities need to be considered)		
		Low (<50 y/o)	Medium (50-70 y/o)	High (>70 y/o)
Risk of Progression With Cancer Care Delay	<b>Low (safe to delay &gt;3 mo)</b> Surgery: Nonmelanoma skin cancer HR+, HER2-, postmenopausal non-locally advanced breast cancer (needs neoadjuvant endocrine therapy on board) Low- or intermediate-risk prostate cancer Type 1 endometrial cancer Low-grade urothelial cancer Most thyroid cancers <3-cm renal mass Stage IA1 cervical cancer  Hematology/Oncology: Chronic hematologic cancer  Radiation Oncology: Nonmelanoma skin cancer HR+, HER2-, postmenopausal non-locally advanced breast cancer (needs neoadjuvant endocrine therapy on board) Low- or intermediate-risk prostate cancer Low-grade lymphoma			
	<b>Intermediate (delay of ~3 mo acceptable)</b> Surgery: High-risk prostate cancer (consider starting androgen deprivation if significant delay) Colon cancer with low risk for imminent obstruction Stage IA2 cervical cancer Low-risk melanoma  Hematology/Oncology: Chemotherapy for advanced breast, colon, lung cancer  Radiation Oncology: Postresection endometrial cancer High-risk prostate cancer (start androgen deprivation)			
	<b>High (ideally, no delay)</b> Surgery: ≥2-cm lung mass Colon cancer with imminent obstruction Type 2 endometrial cancer Pancreatic mass suspicious for malignancy Ovarian masses suspicious for malignancy Liver mass suspicious for malignancy High-risk non-muscle invasive or muscle-invasive urothelial cancer >T1b localized kidney cancer Stage IB cervical cancer Non-low-grade sarcomas  Hematology/Oncology: Chemotherapy for testicular, rectal, all non-low-grade hematologic cancers Non-low grade sarcomas Small cell lung cancer Most head and neck cancers, except thyroid  Radiation Oncology: Lung cancer Rectal cancer Head and neck cancers Gynecologic cancers Non-low-grade sarcomas			



Robust outcomes evidence supporting a decision to initiate or delay cancer care is often lacking. Recommendations in this figure are consensus-based and should be used as a general guideline only. Expert oncologic opinion tailored to individual patient and local health system conditions should always be obtained. COVID-19 = coronavirus 2019; HR+ = hormone receptor-positive; HER- = human epidermal growth factor receptor-negative.

preserve the integrity of the studies while enhancing patient safety during this period.

Implementation of nontraditional care delivery strategies and harnessing of modern information technology platforms, especially for patients who are receiving survivorship care, offers tremendous opportunity to minimize the negative effect of cancer care delivery on public health efforts. For instance, many hospitals and health care systems have prepared telehealth options for their patients. Nationally, the Centers for Medicare & Medicaid Services has expanded telehealth benefits for Medicare beneficiaries during the outbreak, a decision that will allow individuals to receive health care services without traveling to a health care facility. In addition, the U.S. Department of Health

and Human Services will not impose penalties on physicians using telehealth in the event of nonadherence to the Health Insurance Portability and Accountability Act.

### ALLOCATION OF LIMITED HEALTH CARE RESOURCES

Cancer care consumes significant health care resources (9). During the COVID-19 crisis, cancer care utilization of ward and intensive care unit beds, ventilators, pharmaceuticals, blood products, staff, and basic medical supplies may directly conflict with care delivery for those with COVID-19. A new cancer diagnosis is frightening for patients and families. Although most

cancer care is not typically considered “elective,” as resource constraints grow owing to supply chain issues, variations in geographic needs, and reallocation of medical infrastructure to care for infected patients, difficult tradeoffs will need to be made. Education of providers and patients can help in this setting. Similarly, many standard postacute treatment strategies that bring patients into care centers and utilize such resources as laboratory testing, imaging, and office visits can also be thoughtfully postponed to reduce burden on the health care system.

In summary, as cancer care and COVID-19 collide, patients and providers will face extremely difficult choices. The combat plan during this battle must involve patience, communication, diligence, and resolve. Risks must be balanced carefully, public health strategies implemented thoroughly, and resources utilized wisely. Furthermore, the policies and procedures developed today will serve as the basis for addressing the next outbreak or similar crisis.

From Fox Chase Cancer Center, Philadelphia, Pennsylvania (A.K., D.S.W., M.J.E., E.M.H., R.G.U., R.I.F.).

**Acknowledgment:** The authors thank all of their colleagues at Fox Chase Cancer Center, especially J. Robert Beck, MD; Richard Bleicher, MD; Hossein Borghaei, DO; Christina Chu, MD; James Helstrom, MD; Sanjay Reddy, MD; and Patrick McGee.

**Disclosures:** Dr. Kutikov reports personal fees from Merck & Co., Oncosec, and UroToday outside the submitted work. Dr. Fisher reports personal fees from Imedex, Beigene, Portola, Celgene, Barclays, prIME, Gowling WLG, AstraZeneca, and Ion Solutions outside the submitted work. Authors not named here have disclosed no conflicts of interest. Disclosures can also be viewed at [www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M20-1133](http://www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M20-1133).

**Corresponding Author:** Alexander Kutikov, MD, Department of Surgery, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111; e-mail, [alexander.kutikov@fccc.edu](mailto:alexander.kutikov@fccc.edu).

Current author addresses and author contributions are available at [Annals.org](http://Annals.org).

*Ann Intern Med.* doi:10.7326/M20-1133

## References

1. Ferguson NM, Laydon D, Nedjati-Gilani G, et al. Report 9: Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand. Imperial College London. 16 March 2020. Accessed at [www.imperial.ac.uk/mrc-global-infectious-disease-analysis/news-wuhan-coronavirus](http://www.imperial.ac.uk/mrc-global-infectious-disease-analysis/news-wuhan-coronavirus) on 17 March 2020.
2. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. *Lancet Oncol.* 2020;21:335-337. [PMID: 32066541] doi:10.1016/S1470-2045(20)30096-6
3. Di Marco F, Barbaro M. 'It's like a war.' *New York Times.* 17 March 2020. Accessed at [www.nytimes.com/2020/03/17/podcasts/the-daily/italy-coronavirus.html?showTranscript=1](http://www.nytimes.com/2020/03/17/podcasts/the-daily/italy-coronavirus.html?showTranscript=1) on 19 March 2020.
4. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet.* 2020;395:507-513. [PMID: 32007143] doi:10.1016/S0140-6736(20)30211-7
5. Chopra V, Toner E, Waldhorn R, et al. How should U.S. hospitals prepare for coronavirus disease 2019 (COVID-19)? *Ann Intern Med.* 11 March 2020. [Epub ahead of print]. doi:10.7326/M20-0907
6. Stensland KD, Morgan TM, Moinzadeh A, et al. Considerations in the triage of urologic surgeries during the COVID-19 pandemic. *Eur Urol.* 16 March 2020. [Forthcoming]. Accessed at <https://els-jbs-prod-cdn.literatumonline.com/pb/assets/raw/Health%20Advance/journals/eururo/EURUROLO-D-20-00380-1584548684213.pdf> on 27 March 2020.
7. Bootsma MC, Ferguson NM. The effect of public health measures on the 1918 influenza pandemic in U.S. cities. *Proc Natl Acad Sci U S A.* 2007;104:7588-93. [PMID: 17416677]
8. Mooney M, McCaskill-Stevens W. Memorandum: Interim guidance for patients on clinical trials supported by the NCI Cancer Therapy Evaluation Program and the NCI Community Oncology Research Program (NCORP). Public Health Service, U.S. Department of Health and Human Services. 13 March 2020. Accessed at [www.ncicirb.org/system/files/Interim\\_Guidance\\_Clinical\\_Trial\\_Activities\\_Affected\\_%20by\\_Novel\\_Coronavirus\\_3-13-2020\\_0.pdf](http://www.ncicirb.org/system/files/Interim_Guidance_Clinical_Trial_Activities_Affected_%20by_Novel_Coronavirus_3-13-2020_0.pdf) on 18 March 2020.
9. Mariotto AB, Yabroff KR, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010-2020. *J Natl Cancer Inst.* 2011;103:117-28. [PMID: 21228314] doi:10.1093/jnci/djq495

**Current Author Addresses:** Dr. Kutikov: Department of Surgery, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111.

Dr. Weinberg: Department of Medicine, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111.

Dr. Edelman: Department of Hematology/Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111.

Dr. Horwitz: Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111.

Dr. Uzzo: Department of Surgery, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111.

Dr. Fisher: Department of Hematology/Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111.

**Author Contributions:** Conception and design: A. Kutikov, D.S. Weinberg, M.J. Edelman, E.M. Horwitz, R.G. Uzzo, R.I. Fisher.

Analysis and interpretation of the data: D.S. Weinberg, E.M. Horwitz, R.G. Uzzo.

Drafting of the article: A. Kutikov, D.S. Weinberg, M.J. Edelman, E.M. Horwitz, R.G. Uzzo.

Critical revision of the article for important intellectual content: A. Kutikov, D.S. Weinberg, E.M. Horwitz, R.G. Uzzo, R.I. Fisher.

Final approval of the article: A. Kutikov, D.S. Weinberg, M.J. Edelman, E.M. Horwitz, R.G. Uzzo.

Administrative, technical, or logistic support: A. Kutikov, D.S. Weinberg.

Collection and assembly of data: D.S. Weinberg, E.M. Horwitz, R.G. Uzzo.